Naim Hage1, Sebastiaan Winkler1, Paul Gellert2, Snow Stolnik1, and Franco H. Falcone1
1University of Nottingham, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom; 2AstraZeneca, Macclesfield, Cheshire, SK10 2NA, United Kingdom
The aim of our work is to develop a biomimetic drug delivery platform, for targeted delivery to the stomach, based on the bacterium Helicobacter pylori. Thus far, we have demonstrated our recombinant form of the bacterium’s main adhesion protein efficiently binds to specific receptors found on the gastric epithelium. Using this protein to target and localise drug vectors to the stomach represents an innovative approach to solving regionspecific drug absorption through the stomach and proximal small intestine.